BOTULINUM TOXIN TYPE-F FOR TREATMENT OF DYSTONIA - LONG-TERM EXPERIENCE

The authors analyzed retrospectively the results of open-labeled botul inum toxin type F (BTXF) treatment for 1 year or longer in 18 BTXA-res istant patients. All patients except one primary nonresponder to BTXA improved initially with BTXF. Most patients continued to respond to BT XF for 1 year or longer, but four patients became resistant to BTXF. B TXF-resistant patients received a higher dose per treatment and a high er cumulative dose than BTXF-responsive patients. BTXF can he used for longterm treatment of dystonia. It seems prudent to limit BTX doses o f all serotypes to the lowest necessary for clinical efficacy.